Last updated: July 17, 2026

Application No. 17/553,017

T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME AGAINST PRAME POSITIVE CANCERS

Non-Final OA

Filed

Dec 16, 2021

Priority

Mar 23, 2017 — DE 102017106305.6 +2 more

Examiner

WEHBE, ANNE MARIE SABRINA

Art Unit

1634

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

Immatics Biotechnologies GmbH

OA Round

3 (Non-Final)

Interview Optional

— +42.6% interview lift. Interview already conducted in this application's prosecution history. This examiner has a 57% grant rate with +42.6% interview lift. Since an interview has already been tried, recommend written response with narrowed claims based on precedent claim evolution patterns.

Based on 695 resolved cases, 2023–2026

Examiner Intelligence

WEHBE, ANNE MARIE SABRINA View full profile →

Grants 57% of resolved cases

Career Allowance Rate

399 granted / 695 resolved

-2.6% vs TC avg

Strong +43% interview lift

Without

With

+42.6%

Interview Lift

resolved cases with interview

Typical timeline

3y 7m

Avg Prosecution

43 currently pending

Career history

737

Total Applications

across all art units

Statute-Specific Performance

§101

1.1%

-38.9% vs TC avg

§103

52.8%

+12.8% vs TC avg

§102

9.4%

-30.6% vs TC avg

§112

21.9%

-18.1% vs TC avg

Black line = Tech Center average estimate • Based on career data from 695 resolved cases

Prosecution Timeline

Show 3 earlier events

Sep 04, 2025

Applicant Interview (Telephonic)

Sep 06, 2025

Examiner Interview Summary

Sep 19, 2025

Response Filed

Oct 21, 2025

Final Rejection mailed

Jan 16, 2026

Notice of Allowance

May 08, 2026

Request for Continued Examination

May 11, 2026

Response after Non-Final Action

Jun 03, 2026

Non-Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

18/137,110

Patent 12677812

HUMANIZED NON-HUMAN ANIMALS WITH RESTRICTED IMMUNOGLOBULIN HEAVY CHAIN LOCI

3y 2m to grant Granted Jul 14, 2026

18/320,789

Patent 12680107

NON-HUMAN ANIMALS COMPRISING A HUMANIZED ASGR1 LOCUS

3y 1m to grant Granted Jul 14, 2026

18/047,233

Patent 12653904

TARGETING PEPTIDES FOR DIRECTING ADENO-ASSOCIATED VIRUSES (AAVs)

3y 8m to grant Granted Jun 16, 2026

16/472,794

Patent 12642872

VIRUS AAV/IGF2, GENETIC TREATMENT METHOD AND USE THEREOF IN PROTEIN MISFOLDING-RELATED DISEASES, SUCH AS HUNTINGTON'S DISEASE

6y 11m to grant Granted Jun 02, 2026

17/734,392

Patent 12628801

HUMANIZED UNIVERSAL LIGHT CHAIN MICE

4y 0m to grant Granted May 19, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4

Expected OA Rounds

57%

Grant Probability

99%

With Interview (+42.6%)

3y 7m (~0m remaining)

Median Time to Grant

High

PTA Risk

Based on 695 resolved cases by this examiner. Grant probability derived from career allowance rate.